Turtle and colleagues reported on 24 CLL patients, the vast majority (92%) of whom had failed ibrutinib, treated with CD19-BBz CAR T cells after receiving lymphodepleting chemotherapy. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.